Abstract 87P
Background
Glioblastoma is the most common and aggressive primary brain cancer with an overall survival of 15 months despite aggressive cytotoxic treatments. Therefore, identifying new therapeutic targets within the tumor microenvironment (TME) is critical for improving patient outcomes. In glioblastoma, macrophages make up to 30% of the bulk tumor, which include both yolk-sac derived tissue-resident microglia and monocyte-derived macrophages (MDMs) that are recruited from the bone marrow during inflammation. During hematopoiesis, MDMs can arise from granulocyte-monocyte progenitors (GMPs) or monocyte-dendritic cell progenitors (MDPs), which give rise to neutrophil-like or dendritic cell-like lineages, respectively. Although MDMs as a whole are often considered tumor-promoting, the functional role of specific MDM ontogenies is not known. Our recent study identified a subset of MPO+ MDMs associated with better overall survival, enhanced cytotoxic function, and gene expression suggestive of a GMP origin. Therefore, the aim of this study is to characterize the role of MDM ontogeny in brain tumor progression.
Methods
Using a combination of RNA-sequencing, in vitro functional assays and in vivo fate-mapping tools, we assessed the functional role of macrophage ontogeny in glioblastoma models. Additionally, we adoptively transferred monocytes cultured ex vivo from distinct developmental origins to trace their recruitment to tumors and assess the subsequent impact on tumor growth.
Results
Interestingly, macrophage ontogeny was associated with differences in MHC I-mediated and MHC II-mediated antigen presentation as well as unique profile of cytokines and chemokines, including MPO. Additionally, we found differences in phagocytosis towards glioma cells and upregulation of different inflammatory pathways. Importantly, adoptive transfer of monocytes of distinct ontogenies had opposing effects on brain tumor progression and resulted in significant changes to the TME and peripheral immune system.
Conclusions
Our findings shed light on the developmental origins of brain tumor MDMs and their putative regulatory impact in the TME.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Brain Tumour Foundation of Canada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract